{"filing":{"accession_number":"0001628280-26-056953","cik":"0001411685","ticker":"VTGN","company_name":"Vistagen Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"vtgn-20260814.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026056953/vtgn-20260814.htm"},"events":[{"id":27775,"run_id":25350,"accession_number":"0001628280-26-056953","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Vistagen's fiscal year 2027 first quarter ended June 30, 2026, disclosing financial results including revenue of $1.5 million, R\u0026D expense of $10.9 million, G\u0026A expense of $3.9 million, and a net loss of $13.0 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes condensed consolidated balance sheets and statements of operations, and the company provides forward-looking guidance on cash runway and expense trends.","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29447,"accession_number":"0001628280-26-056953","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Vistagen's fiscal year 2027 first quarter ended June 30, 2026, disclosing financial results including revenue of $1.5 million, R\u0026D expense of $10.9 million, G\u0026A expense of $3.9 million, and a net loss of $13.0 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes condensed consolidated balance sheets and statements of operations, and the company provides forward-looking guidance on cash runway and expense trends.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:41:38.575884+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29447,"accession_number":"0001628280-26-056953","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Vistagen's fiscal year 2027 first quarter ended June 30, 2026, disclosing financial results including revenue of $1.5 million, R\u0026D expense of $10.9 million, G\u0026A expense of $3.9 million, and a net loss of $13.0 million. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures. The filing includes condensed consolidated balance sheets and statements of operations, and the company provides forward-looking guidance on cash runway and expense trends.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T12:41:38.575884+00:00","company_name":"Vistagen Therapeutics, Inc.","ticker":"VTGN","filing_date":"2026-08-14"}]}